&lt;p&gt;LINC00565 promotes proliferation and inhibits apoptosis of gastric cancer by targeting miR-665/AKT3 axis&lt;/p&gt;

Hu, Jianghong; Ni, Guohua; Mao, Ling; Xue, Xindong; Zhang, Jijie; Wu, Weixia; Zhang, Shaoru; Zhao, Hong; Ding, Lin‐Fen; Wang, Lihui

doi:10.2147/ott.s189471

Cited by 23 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 LINC00565 is a tumorassociated lncRNA involved in the development of ovarian cancer and gastric cancer. 17,18 We collected 52 paired EC tissues and paracancerous tissues and detected the relative levels of LINC00565 and KLF9 in EC tissues. LINC00565 was up-regulated and KLF9 was down-regulated in EC tissues.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>LINC00565 Enhances Proliferative Ability in Endometrial Carcinoma by Downregulating KLF9</p>

Yin¹,

Li²,

Feng³

et al. 2020

OTT

View full text Add to dashboard Cite

To detect LINC00565 expression level in endometrial carcinoma (EC) samples and cell lines, and the correlations between LINC00565 and clinical features of EC patients. After intervening LINC00565, the underlying mechanism about proliferative ability in EC cell lines is observed. Methods: Relative levels of LINC00565 and KLF9 in 52 paired EC and paracancerous tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between relative level of LINC00565 or KLF9 and clinical features of EC patients was analyzed. After knockdown of LINC00565 and KLF9, potential regulations of them on biological functions of EC were examined by Cell Counting Kit (CCK-8), colony formation assay and in vivo xenograft model in nude mice, respectively. At last, dualluciferase reporter assay and rescue experiments were conducted to illustrate the mechanisms of LINC00565 and KLF9 in mediating the development of EC. Results: LINC00565 was upregulated in EC tissues. Chi-square analysis showed that a high level of LINC00565 predicted large tumor size, advanced pathological staging and poor prognosis in EC. Silence of LINC00565 decreased proliferative ability in EC cells and tumor growth in nude mice bearing EC. KLF9 was the target gene of LINC00565. The negative interaction between LINC00565 and KLF9 was responsible for stimulating the malignant development of EC. Knockdown of KLF9 could abolish the regulatory effects of silenced LINC00565 on proliferative ability and tumorigenesis in EC. Conclusion: LINC00565 is upregulated in EC tissues and closely linked to tumor size, pathological staging and poor prognosis in EC patients. LINC00565 stimulates proliferative ability in EC by downregulating KLF9.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[13][14][15][16] It is previously reported that LINC00565 is an oncogene triggering deterioration of tumor development. 17,18 However, its potential role in EC remains unclear.…”

Section: Introductionmentioning

confidence: 99%

<p>LINC00565 Enhances Proliferative Ability in Endometrial Carcinoma by Downregulating KLF9</p>

Yin¹,

Li²,

Feng³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…To comprehensively characterize those aberrantly expressed lncRNAs, we analyzed CRC and normal tissue RNA sequencing data downloaded from The Cancer Genome Atlas (TCGA). In order to identify CRC-associated lncRNAs, the literature was searched to identify a novel lncRNA named LINC00565 has already been discovered in gastric cancer ( 13 ). LINC00565 spans 2,478 bp length and is located on chromosome 13, which is significantly upregulated in gastric cancer (GC) tissues ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

“…In order to identify CRC-associated lncRNAs, the literature was searched to identify a novel lncRNA named LINC00565 has already been discovered in gastric cancer ( 13 ). LINC00565 spans 2,478 bp length and is located on chromosome 13, which is significantly upregulated in gastric cancer (GC) tissues ( 13 ). LINC00565 drives the progression of ovarian cancer by targeting GAS6 ( 14 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

LINC00565 promotes the progression of colorectal cancer by upregulating EZH2

et al. 2020

View full text Add to dashboard Cite

The present study aimed to illustrate the role of LINC00565 in aggravating colorectal cancer (CRC) by targeting enhancer of zeste homolog 2 (EZH2). The relative levels of LINC00565 and EZH2 in CRC tissues, based on their Tumor-Node-Metastasis stage and tumor size, were detected by reverse transcription-quantitative polymerase chain reaction. The diagnostic value of LINC00565 in CRC was assessed by depicting receiver operating characteristic curves. Pearson's correlation test was applied to analyze the expression correlation between LINC00565 and EZH2 in CRC tissues. The transfection efficacy of three LINC00565 small interfering RNAs was examined in CRC HCT116 and SW480 cell lines. After knockdown of LINC00565, the proliferative and migratory abilities of CRC cells were detected by Cell Counting Kit-8 and Transwell assays, respectively. The subcellular distribution of LINC00565 was analyzed, and the interaction between LINC00565 and EZH2 was determined by RNA immunoprecipitation. Finally, co-regulation of LINC00565 and EZH2 on CRC cell functions was explored by performing rescue experiments. Results showed that LINC00565 was upregulated in CRC tissues, especially in patients with stage III+IV and in those with large tumor sizes, suggesting its diagnostic value in CRC. EZH2 was also upregulated in CRC tissues, showing a positive correlation with LINC00565. LINC00565 was mainly expressed in the cytoplasm and was found to bind with EZH2. Validation was performed by overexpressing EZH2, which abolished the role of silenced LINC00565 in regulating proliferative and migratory abilities in CRC. Therefore, the upregulation of LINC00565 in CRC tissues was found to stimulate the aggravation of CRC by upregulating EZH2.

show abstract

Construction of a cuproptosis‐related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients

Hong

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background: Long noncoding RNAs (lncRNAs) influence the onset of osteosarcoma. Cuproptosis is a novel cell death mechanism. We attempted to identify a cuproptosis-related lncRNA signature to predict the prognosis and immune landscape in osteosarcoma patients. Methods:Transcriptional and clinical data of 85 osteosarcoma patients were derived from the TARGET database and randomly categorized into the training and validation cohorts. We implemented the univariate and multivariate Cox regression, along with LASSO regression analyses for developing a cuproptosis-related lncRNA risk model. Kaplan-Meier curves, C-index, ROC curves, univariate and multivariate Cox regression, and nomogram were used to assess the capacity of this risk model to predict the osteosarcoma prognosis. Gene ontology, KEGG, and Gene Set Enrichment (GSEA) analyses were conducted for determining the potential functional differences existing between the high-risk and low-risk patients.We further conducted the ESTIMATE, single-smaple GSEA, and CIBERSORT analyses for identifying the different immune microenvironments and immune cells infiltrating both the risk groups. Results:We screened out four cuproptosis-related lncRNAs (AL033384.2, AL031775.1, AC110995.1, and LINC00565) to construct the risk model in the training cohort. This risk model displayed a good performance to predict the overall survival of osteosarcoma patients, which was confirmed by using the validation and the entire cohort. Further analyses showed that the low-risk patients have more immune activation and immune cells infiltrating as well as a good response to immunotherapy. Conclusions:We developed a novel cuproptosis-related lncRNA signature with high reliability and accuracy for predicting outcome and immunotherapy response in osteosarcoma patients, which provides new insights into the personalized treatment of osteosarcoma.

show abstract

<p>LINC00565 promotes proliferation and inhibits apoptosis of gastric cancer by targeting miR-665/AKT3 axis</p>

Cited by 23 publications

References 36 publications

<p>LINC00565 Enhances Proliferative Ability in Endometrial Carcinoma by Downregulating KLF9</p>

<p>LINC00565 Enhances Proliferative Ability in Endometrial Carcinoma by Downregulating KLF9</p>

LINC00565 promotes the progression of colorectal cancer by upregulating EZH2

Construction of a cuproptosis‐related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients

Contact Info

Product

Resources

About